Understanding Sentinel Lymph Node Biopsy for Melanoma

Sentinel lymph node biopsy (SLNB) is a surgical staging procedure used to determine whether melanoma has spread from the original skin tumor to nearby lymph nodes. It identifies and removes the first lymph node or group of nodes that receive lymphatic drainage from the tumor area. The findings provide important information about melanoma staging, recurrence risk, and whether additional treatment or monitoring may be appropriate.

Unlike a complete lymph node dissection, sentinel lymph node biopsy removes only selected nodes for pathological examination rather than an entire group of regional lymph nodes. This provides staging information while generally reducing the extent of surgery and the risk of certain complications.

At Saint John’s Cancer Institute, melanoma specialists consider the primary tumor’s thickness, ulceration, pathology findings, and other clinical factors when recommending lymph node evaluation. The procedure is usually coordinated with surgical treatment of the original melanoma when indicated.

Why Are Sentinel Lymph Nodes Important?

Illustration showing lymphatic drainage from a melanoma tumor to sentinel lymph nodes — Sentinel lymph nodes are the first lymph nodes that receive drainage from the area of the primary melanoma.

Lymph nodes are small structures that filter lymphatic fluid and contain immune cells. Melanoma cells can sometimes travel through lymphatic channels from the primary skin lesion to regional lymph nodes before there are visible or palpable signs of spread.

The sentinel nodes are identified according to the pattern of lymphatic drainage rather than simply their physical distance from the tumor. Depending on the location of the melanoma, drainage may reach lymph nodes in the neck, underarm, groin, or more than one regional basin.

Finding melanoma in a sentinel lymph node changes the pathological stage and can affect recommendations for postoperative treatment and surveillance. A negative result reduces concern about microscopic regional lymph node involvement but does not eliminate the possibility of future recurrence.

When Is Sentinel Lymph Node Biopsy Recommended?

Sentinel lymph node biopsy is not necessary for every melanoma. One of the principal considerations is Breslow thickness, which measures how deeply the melanoma extends into the skin. Ulceration and other findings can also influence the recommendation.

Recommendations generally include:

Nonulcerated Melanoma Under 0.8 mm: SLNB is not routinely recommended because the likelihood of sentinel lymph node involvement is relatively low. Selected additional risk factors may warrant discussion.
Melanoma 0.8–1.0 mm or Ulcerated Tumors Under 0.8 mm: SLNB should be discussed with the patient, taking into account potential benefits, risks, and the individual pathology findings.
Melanoma Greater Than 1.0 mm: SLNB is generally recommended or offered for appropriate patients without clinically detectable lymph node metastases. The decision may still be individualized according to the stage, treatment plan, and circumstances.

These recommendations apply to cutaneous melanoma and are not necessarily the same for other skin cancers. If lymph nodes are already enlarged or suspicious for metastasis, needle biopsy and other staging studies may be more appropriate than a routine sentinel lymph node biopsy.

Benefits and Limitations of Sentinel Lymph Node Biopsy

The principal benefit of SLNB is identifying microscopic lymph node involvement that cannot be detected during a routine physical examination. Accurate staging can help patients and clinicians understand recurrence risk and determine whether additional therapies or surveillance strategies should be considered.

Compared with removing an entire regional lymph node basin, SLNB generally involves a smaller operation and carries a lower risk of complications, particularly lymphedema. However, it is still a surgical procedure and cannot guarantee that melanoma will not recur.

Sentinel lymph node biopsy should not be described as automatically improving survival for every patient. Its value lies primarily in accurate staging, prognosis, and informing subsequent treatment decisions.

What to Expect During Sentinel Lymph Node Biopsy

Sentinel lymph node biopsy is commonly performed as an outpatient procedure, often during the same operation as wide local excision of the primary melanoma. The procedure uses lymphatic mapping to identify the first draining lymph nodes, which are then removed and examined for microscopic cancer cells. The specific approach depends on the location of the melanoma and the patient’s surgical plan.

Locating the Sentinel Lymph Nodes

Anatomical illustration of lymph nodes in the underarm region — Regional lymph nodes are found in areas such as the neck, underarms, and groin.

Before surgery, a small amount of radioactive tracer is commonly injected into the skin near the melanoma or its biopsy site. The tracer travels through the lymphatic channels toward the sentinel nodes. Imaging called lymphoscintigraphy may be performed to identify the draining lymph node basin.

During surgery, a handheld detection device helps the surgeon locate nodes containing the tracer. Blue dye or other mapping techniques may also be used when appropriate. These methods allow the surgeon to identify the nodes most likely to receive lymphatic drainage from the original tumor.

More than one sentinel node may be identified, and some melanomas drain to multiple lymph node basins. The mapping findings guide which nodes should be removed for examination.

Removing and Examining the Sentinel Nodes

The procedure is generally performed under anesthesia. After identifying the sentinel nodes, the surgeon makes one or more small incisions and removes the selected nodes. When appropriate, wide local excision of the primary melanoma is performed during the same operation.

A pathologist examines the removed lymph nodes for melanoma cells. Specialized stains may be used to identify small deposits that would not necessarily be apparent during a routine examination.

Because the complete pathological evaluation may require additional processing, final results are generally discussed at a postoperative appointment rather than assumed to be available immediately after surgery.

What Do Positive and Negative Results Mean?

A negative sentinel lymph node biopsy means melanoma was not identified in the lymph nodes examined. This is reassuring and helps establish the pathological stage, although it cannot completely rule out microscopic disease elsewhere or future recurrence.

A positive sentinel lymph node biopsy means melanoma cells were found in one or more sampled nodes. This establishes regional lymph node involvement and may change the melanoma stage, estimated recurrence risk, and recommendations for additional treatment or surveillance.

Importantly, a positive sentinel node does not automatically mean that all remaining lymph nodes must be removed. Research has shown that many appropriately selected patients can undergo close clinical examination and lymph node ultrasound surveillance rather than immediate completion lymph node dissection.

Additional treatment may include immunotherapy or, for eligible melanomas with particular molecular alterations, targeted therapy. Recommendations depend on the stage, tumor characteristics, and the patient’s overall circumstances.

Learn more about Completion Lymph Node Dissection and how its role in melanoma treatment has changed.

Recovery and Possible Side Effects

Most patients return home on the day of surgery, although individual recovery depends on the procedure and whether additional surgery was performed. Some discomfort, bruising, or temporary restrictions on activity may occur near the incision sites.

Possible side effects and complications include:

Pain or Tenderness: Temporary discomfort around the surgical incision.
Bruising or Swelling: Changes in the tissues surrounding the procedure site.
Infection or Bleeding: Uncommon complications that may require medical attention.
Seroma: A collection of fluid near the incision that may occasionally require drainage.
Altered Sensation: Numbness, tingling, or sensitivity caused by irritation of nearby nerves.
Lymphedema: Swelling caused by disruption of lymphatic drainage, which is less common after SLNB than after more extensive lymph node surgery.
Mapping Dye Reactions: Temporary skin discoloration or, rarely, an allergic reaction if blue dye is used.

Patients receive instructions on incision care, pain management, activity, and symptoms that require medical attention. Increasing redness, fever, significant swelling, uncontrolled pain, or unexpected drainage should be reported to the surgical team.

Returning to Normal Activities

Many patients can resume light daily activities relatively soon after sentinel lymph node biopsy, depending on the location of the incisions and any accompanying procedures. The surgical team may recommend temporarily limiting strenuous exercise, lifting, or movements that place tension on the incision.

Recovery instructions should be tailored to the individual operation. Patients should also understand when their pathology results will be available and when follow-up evaluation is scheduled.

The Development of Sentinel Lymph Node Biopsy at Saint John’s

Sentinel lymph node biopsy has an important history at Saint John’s Cancer Institute. Research conducted by Donald L. Morton, MD, and his colleagues helped establish a method for identifying the first lymph nodes that receive drainage from a melanoma. This work contributed to a major change in surgical oncology by allowing physicians to evaluate regional lymph node involvement without routinely removing an entire lymph node basin.

Donald Morton’s Contribution to Melanoma Surgery

In 1992, Dr. Morton and his colleagues published their research describing intraoperative lymphatic mapping for early-stage melanoma. By using a special dye to identify sentinel lymph nodes, surgeons could selectively remove and examine those nodes for cancer cells.

The technique provided a way to identify patients with microscopic lymph node involvement while sparing many patients from more extensive surgery when their nodes were free of melanoma. Subsequent research helped refine mapping with radioactive tracers, improve detection, and extend the technique’s use in melanoma and other cancers.

Dr. Morton’s work, conducted through the former John Wayne Cancer Institute and collaborating institutions, became an important foundation for modern sentinel lymph node surgery. His research also helped establish the clinical questions investigated in subsequent international melanoma trials.

How the MSLT Clinical Trials Changed Melanoma Care

The Multicenter Selective Lymphadenectomy Trials (MSLT) helped evaluate how sentinel lymph node biopsy and additional lymph node surgery influence melanoma management. These studies contributed evidence about regional disease control, prognostic information, and the risks and benefits of removing additional lymph nodes.

MSLT-I helped establish the clinical value of sentinel lymph node evaluation in appropriately selected patients. MSLT-II subsequently demonstrated that immediate completion lymph node dissection did not improve melanoma-specific survival compared with careful nodal ultrasound observation among patients with sentinel node metastases enrolled in the trial.

Together, these studies contributed to a more selective approach to regional lymph node surgery. Sentinel lymph node biopsy remains important for staging many melanomas, while decisions about further surgery depend on the individual clinical findings and available treatment options.

Coordinated Melanoma Evaluation

At Saint John’s Cancer Institute, sentinel lymph node biopsy and melanoma staging may involve coordination among surgical oncologists, pathologists, nuclear medicine specialists, medical oncologists, and other members of the care team.

The findings can help determine whether additional imaging, surveillance, immunotherapy, targeted therapy, or other treatment should be considered. For patients with complex or higher-risk disease, multidisciplinary discussion can help clarify these decisions.

Questions to Discuss Before Sentinel Lymph Node Biopsy

Patients considering SLNB may wish to understand why it is recommended, how their melanoma thickness and pathology affect the decision, and what the results could mean for subsequent treatment.

Other useful questions include whether the procedure will be performed with wide local excision, how many lymph node areas may require evaluation, what complications are possible, and whether additional surgery would be necessary if melanoma is found.

Get Answers About Sentinel Lymph Node Biopsy

Learning that your melanoma may require lymph node evaluation can raise important questions about staging, surgery, and the possibility of cancer spread. Understanding why sentinel lymph node biopsy is recommended and how its findings influence treatment can help you make informed decisions about your care.

At Saint John’s Cancer Institute, our melanoma specialists work together to evaluate complex cases and develop individualized recommendations, drawing on the Institute’s established history of research in sentinel lymph node mapping and melanoma surgery.

If you have questions regarding the evaluation or treatment for melanoma, please call today or click here to schedule an appointment or for an expert second opinion.

310-829-8317